Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparative Study About the Influence of Diabetes Diatress and Depression on Treatment Adherence in Chinese Type 2 Diabetes Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
cuiping-xu, Shandong Provincial Hospital
ClinicalTrials.gov Identifier:
NCT01755351
First received: December 18, 2012
Last updated: January 2, 2013
Last verified: January 2013
  Purpose

An effective treatment adherence was a key to make the treatment success, some reports had shown that psychologicl factors impact patients adherence seriously,however, in China, the researches were only limited to depression and diabetes,diabetes distress was neglected. Some western studies had demonstrated the impact of diabetes distress on diabetes. Thus, we hypothesized that: 1.perhaps our present depression-oriented health education was inadequate to promote patients' adherence, diabetes distress might played a more important part than depression in patients' treatment adherence. 2. there might be a high prevalence of diabetes distress in Chinese type 2 diabetes; so, the comparative study between diabetes distress and depresion was conducted.

Objectives: to explore the relationship of diabetes-related distress and depression,and to compare the influence of diabetes distress and depression on treatment adherence in Chinese type 2 diabetes .

Research design and method:we surveyed 200 type 2 diabetic patients from 2 third-class hospitals using the Diabetes Distress Scale, Zung Self-rating Depression Scale, and Revised Treatment Adherence in Diabetes Questionnaire (RADQ)simultaneously.


Condition
Compare Diabetes Distress and Depression

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Target Follow-Up Duration: 1 Year

Resource links provided by NLM:


Further study details as provided by Shandong Provincial Hospital:

Primary Outcome Measures:
  • The influence of diabetes distress on treatment sdherence [ Time Frame: 6 month ] [ Designated as safety issue: Yes ]

Enrollment: 200
Study Start Date: December 2011
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

patients with type 2 diabetes who visited the two local hospitals between December 2011 and April 2012, were invited to participate in this cross-sectional survey study.

Criteria

Inclusion Criteria:

  • 1)aged between 18-80 years, 2)diagnosed with diabetes for at least 6 month, 3) having the ability to communicate fluently and clearly,

Exclusion Criteria:

  • patients who had the diagnosis of dementia or psychosis and severe diabetes complications (e.g., on dialysis)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01755351

Locations
China
Qianfoshan Hospital Shandong province
Jinan, China
Sponsors and Collaborators
Shandong Provincial Hospital
  More Information

No publications provided

Responsible Party: cuiping-xu, Qianfoshan Hospital, Shandong Provincial Hospital
ClinicalTrials.gov Identifier: NCT01755351     History of Changes
Other Study ID Numbers: ShandongPH
Study First Received: December 18, 2012
Last Updated: January 2, 2013
Health Authority: China: Qianfoshan Hospital

Additional relevant MeSH terms:
Depression
Depressive Disorder
Diabetes Mellitus
Behavioral Symptoms
Endocrine System Diseases
Glucose Metabolism Disorders
Mental Disorders
Metabolic Diseases
Mood Disorders

ClinicalTrials.gov processed this record on November 20, 2014